1. January 27, 2023

    PRAC January 2023 - recommendations for Janus kinase (JAK) inhibitors and information about Zolgensma

    Alignment of dose recommendations for Janus kinase (JAK) inhibitors in patients with certain risk factors
    EMA’s safety committee (PRAC) has further reviewed measures to minimise the risk of serious side effects associated with Janus kinase (JAK) inhibitors used to treat several chronic inflammatory disorders.

    Source: FAMHP

    Read more

  2. January 17, 2023

    IFAPP Today newsletter - January 2023

    Source: IFAPP

    Please find here the link to the IFAPP TODAY newsletter of January 2023.

    Read more

  3. January 12, 2023

    COVID-19: Audit Hospitals re-estimates hospital care not provided

    Deze audit onderzoekt de niet-uitgevoerde ziekenhuiszorg en gecumuleerde potentiële zorgachterstanden vanaf het begin van de pandemie tot en met de zesde golf (van mei 2021 tot en met mei 2022). 

    L’audit porte sur les soins non effectués et les retards accumulés dans les hôpitaux depuis le début de la pandémie jusqu’à la sixième vague incluse (de mai 2021 à mai 2022).

    Source: FAMHP

    Read more

  4. January 10, 2023

    IFAPP virtual training workshop: Introduction to the new EU Clinical Trial Regulation

    From 31 January 2023 all clinical trials with medicines must be authorised, handled and reported according to the rules lined out in the Regulation EU No 536/2014 (Clinical Trials Regulation).

    Read more

  5. January 10, 2023

    Indexation of hospitality amounts, fees to apply for Mdeon visum and sponsoring virtual and hybrid meetings.

    As from January 1st, 2023, a number of novelties will take effect regarding the amounts for hospitality, the amounts of the fees to apply for an Mdeon visum and the sponsoring of virtual and hybrid meetings.

    Read more

  6. January 10, 2023

    Healixia Clinical Conference 2022: full report now available for download!

    Our Clinical Conference on October 20th 2022 was a success and we are happy to share a bit of it with you!

    Read more

  7. January 9, 2023

    Belgium publishes the first report on antimicrobial resistance

    Antimicrobiële resistentie, ook AMR genoemd, is één van de grootste bedreigingen voor de volksgezondheid. Daarom werd in samenwerking met verschillende Belgische autoriteiten een nationaal actieplan ontwikkeld. België publiceert het eerste “One Health”-rapport over AMR om de resultaten samen te vatten.

    La résistance aux antimicrobiens, également appelée AMR, est l’une des principales menaces pour la santé publique. C’est pourquoi un plan national d’action a été développé en collaboration avec différentes autorités belges. La Belgique publie aujourd’hui son premier rapport « One Health » sur l’AMR pour synthétiser les résultats.

    Source: FAMHP

    Read more

  8. December 23, 2022

    Medical Affairs survey in collaboration with NVFG

    Fill out the survey aims to map, for the first time in Benelux, the Medical Affairs professional and collect insight on demographics, role & responsibilities, education and other aspects. Target audience are Medical Advisors, Medical Science Liaisons and other Medical Affairs professionals; active in Benelux.

    Read more

  9. December 23, 2022

    Operation Shield III: Belgian authorities seize 145,054 illegal products in action against counterfeit drugs and doping

    De Douane, de Federale Politie, het Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (FAGG) en het Federaal Agentschap voor de Veiligheid van de Voedselketen (FAVV) hebben deelgenomen aan operatie SHIELD III, gecoördineerd door Europol. Deze actie liep van april tot oktober 2022 en was gericht tegen namaakgeneesmiddelen en doping.

    Les douanes, la police fédérale, l'Agence fédérale des médicaments et des produits de santé (AFMPS) et l'Agence fédérale pour la sécurité de la chaîne alimentaire (AFSCA) ont participé à l'opération SHIELD III, coordonnée par Europol. Cette opération s'est déroulée d'avril à octobre 2022 et visait les médicaments contrefaits et le dopage.

    Source: FAMHP

    Read more

  10. December 23, 2022

    FAMHP reminds of need for customer declaration for buyers of category 1 or 2 chemicals

    Distributors and vendors of category 1 or 2 chemicals must require the buyer to provide a customer declaration of specific use. This is legally required by Regulation (EC) No 273/2004 and aims to protect trade in drug precursors (substances that can be used to make drugs).

    Read more